37589-22-3

Basic information

• Product Name: 1-phenyl-3-adamantanecarboxylicaci
• Synonyms: 1-phenyl-3-adamantanecarboxylicaci;1-Phenyl-3-adamantanecarboxylic acid;3-phenyladamantane-1-carboxylic acid(SALTDATA: FREE)
• CAS NO: 37589-22-3
• Molecular Formula: C₁₇H₂₀O₂
• Molecular Weight: 256.34
• Mol File: 37589-22-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 408.8°Cat760mmHg
• Flash Point: 190.1°C
• Appearance: /
• Density: 1.248g/cm³
• Vapor Pressure: 2.04E-07mmHg at 25°C
• CAS DataBase Reference: 1-phenyl-3-adamantanecarboxylicaci(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-3-adamantanecarboxylicaci(37589-22-3)
• EPA Substance Registry System: 1-phenyl-3-adamantanecarboxylicaci(37589-22-3)

Safety Data

• Hazardous Substances Data: 37589-22-3(Hazardous Substances Data)

Usage

Structure

Adamantanecarboxylic acid with a phenyl group attached to the third position of the carbon chain A description of the compound's arrangement of atoms and functional groups.

Physical appearance

White powder The form and color of the compound when isolated from its purest state.

Molecular weight

296.407 g/mol The mass of one mole of the compound, expressed in grams.

Usage in organic synthesis and pharmaceutical research

Building block for the synthesis of various compounds The compound's role in creating other molecules, which can be used in drug development and other applications.

Pharmacological activities

Anticancer and antiviral properties The potential therapeutic effects of the compound in inhibiting cancer cell growth and combating viral infections.

Further research needed

To fully understand its therapeutic potential and biological activities A statement highlighting the need for more studies to explore the compound's possible applications and effects on living organisms.

InChI:InChI=1/C17H20O2/c18-15(19)17-9-12-6-13(10-17)8-16(7-12,11-17)14-4-2-1-3-5-14/h1-5,12-13H,6-11H2,(H,18,19)/p-1/t12-,13+,16?,17?

Upstream product

• 21816-08-0 3-bromoadamantane-1-carboxylic acid 
• 108-90-7 chlorobenzene 
• 71-43-2 benzene 

Downstream Products

• 29835-32-3 3-phenyl-1-tricyclo[3.3.1.1^3,7]decanecarboxaldehyde 
• 1449651-21-1 4,5-dihydro-1-methyl-5-(3-phenyl-1-tricyclo[3.3.1.1^3,7]decyl)-1H-2-imidazolamine hydrobromide 
• 1449651-19-7 4,5-dihydro-1,2-dimethyl-5-(3-phenyl-1-tricyclo[3.3.1.1^3,7]decyl)-1H-imidazole hydrochloride 
• 1449651-18-6 4,5-dihydro-1,2-dimethyl-5-(3-phenyl-1-tricyclo[3.3.1.1^3,7]decyl)-1H-imidazole 
• 1449651-15-3 4,5-dihydro-1-methyl-5-(3-phenyl-1-tricyclo[3.3.1.1^3,7]decyl)-1H-imidazoline hydrochloride 
• 1449651-14-2 4,5-dihydro-1-methyl-5-(3-phenyl-1-tricyclo[3.3.1.1^3,7]decyl)-1H-imidazoline 
• 1449651-11-9 5-(3-cyclohexyl-1-tricyclo[3.3.1.1^3,7]decyl)-4.5-dihydro-1-methyl-1H-2-imidazolamine hydrobromide 
• 1449651-10-8 5-(3-cyclohexyl-1-tricyclo[3.3.1.1^3,7]decyl)-4,5-dihydro-1H-2-imidazolamine hydrobromide 
• 27011-59-2 3-phenyl-1-tricyclo[3.3.1.1^3,7]decanemethanol 
• 1449651-09-5 5-(3-cyclohexyl-1-tricyclo[3.3.1.1^3,7]decyl)-4,5-dihydro-1H-imidazole hydrochloride 
• 1449651-08-4 5-(3-cyclohexyl-1-tricyclo[3.3.1.1^3,7]decyl)-4,5-dihydro-1H-imidazole 
• 1449650-87-6 a-methylamino-3-phenyl-1-tricyclo [3.3.1.1^3,7]decaneacetonitrile hydrochloride 
• 1449650-86-5 a-amino-3-phenyl-1-tricyclo[3.3.1.1^3,7]decaneacetonitrile hydrochloride 

Relevant articles and documents

METHODS OF INDUCING AN ANTI-CANCER IMMUNE RESPONSE

A method or preparing immunologically primed cancer cells using cancer cells collected from a patient includes treating the collected cancer cells, ex vivo, with a toxic concentration of a compound that modifies sphingolipid metabolism, wherein the toxic concentration is sufficient to induce immunogenic cell death in the cancer cells. In an embodiment, the compound is 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acid(pyridin-4-ylmethyl)-amide compound or a pharmaceutically acceptable salt thereof. In an embodiment, the immunologically primed cancer cells overexpress calreticulin on their surface. In an embodiment, the cancer cells are solid tumor cells. In an embodiment, the cancer cells are circulating tumor cells. In an embodiment, the method further comprises harvesting at least a portion of the immunologically primed cancer cells; and suspending the cells in phosphate-buffered saline. In an embodiment, the method further comprises shipping at least a portion of the immunologically primed cancer cells to a point of the patient's care.